CLVS - Clovis Oncology, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue78-13,625
Cost of Revenue70--
Gross Profit8-13,625
Operating Expenses
Research Development251,129269,251137,705
Selling General and Administrative15,7955,91322,164
Non Recurring105,817101,55712,215
Total Operating Expenses---
Operating Income or Loss-372,733-376,721-158,459
Income from Continuing Operations
Total Other Income/Expenses Net533,1563,340
Earnings Before Interest and Taxes-372,680-373,565-155,119
Interest Expense8,4918,3722,604
Income Before Tax-381,171-381,937-157,723
Income Tax Expense-32,034-29,0762,308
Minority Interest---
Net Income From Continuing Ops-349,137-352,861-160,031
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-349,137-352,861-160,031
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-349,137-352,861-160,031